All News

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

Laura B. Herpel, MD, reviews REFRESH trial data on once-nightly oxybate in narcolepsy, focusing on daytime function, stimulant reduction, and mental health.

FDA approved teplizumab to help preserve insulin production in children with recent-onset stage 3 type 1 diabetes.

Patil reviews 3 new AASM guidelines at SLEEP 2026 covering updated CSA treatment, first-ever inpatient OSA guidance, and chronic insomnia therapy hierarchy.

Andrew Ho, MD, reviews single-center data showing GLP-1 coverage barriers reshaped OSA referral patterns, with symptom documentation absent in most cases.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Wearable sleep tracker use was linked to better sleep in patients with insomnia and COMISA, while OSA showed a divergent pattern warranting further study.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

New research suggests EDS combined with prolonged sleep-onset latency is linked to 3x greater risk of incident hypertension and 2x greater risk of prevalent hypertension.

The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.